KURA logo

KURA ONCOLOGY INC

KURANASDAQ
🏆 #2519 by market capEarnings Oct 29US Equity
$133.93▼ $5.93 (−4.43%)
Simulated price
🔔
Track KURA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.4%
7d▲ 1040.8%
14d▲ 1084.2%
30d▲ 959.2%
ytd▲ 1190.3%
1y▲ 1391.4%
🏦Market Cap
$944M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
12.2x
Elevated
Otter Score
64
Fair

Trading Snapshot

Day Range
$132.54 – $134.60
52-Week Range
$7.36 – $13.90
Volume
$1.94B
Avg Volume
$2.42B
Shares Outstanding
88.8M
Next Earnings
Oct 18, 2026

Fundamentals Snapshot

Annual Revenue
$67M
Last Q Revenue
$21M
P/E Ratio
—
P/S Ratio
12.2x
EPS (TTM)
$-3.36
Dividend Yield
—
Dilution (1yr)
+1.0%

Why Investors Own KURA

  • ✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 39% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KURA logo

KURA ONCOLOGY INC

KURA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$67M▲ +25.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.9%▼ −0.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$304M▲ +57.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$71M▼ −152.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
88.0M▲ +1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$129M▼ −$79M YoY
StockOtter · stockotter.space

About KURA ONCOLOGY INC

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
22 analysts
Strong Buy6
Buy13
Hold3
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

KURA ONCOLOGY INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift KURA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

KURA ONCOLOGY INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.